分子检测结果报告:BRAF突变报告回顾性审查
该研究回顾性审查了参加CAP BRAF突变能力验证的实验室提交的107份最终报告,评估其是否包含向临床传达分子检测结果所需的关键要素。结果显示多数报告包含方法(95%)和靶标(87%)描述,但分析灵敏度(74%)和未检测变异(34%)的报告率较低。结论认为实验室已纳入大部分必需报告要素,但仍需追求简洁全面的报告方式。
要点
- 107份BRAF能力验证报告中,95%充分描述检测方法,87%充分描述检测靶标。
- 仅74%报告包含分析灵敏度信息,34%报告提及未检测的变异。
- 99%报告包含分析性解释,90%报告包含临床解释性评论。
核心结论
- 参加CAP BRAF能力验证的实验室已纳入大部分必需报告要素,能明确传达分子结果。
- 实验室应继续努力以简洁全面的方式报告分子检测结果。
研究设计与样本
- 回顾性审查研究,纳入参加CAP BRAF突变能力验证项目的实验室提交的2个能力验证周期最终报告。
- 共收到107份可评估报告,其中57份BRAF V600E突变阳性,50份阴性。
主要发现
- 95%(102/107)报告充分描述检测方法,87%(93/107)充分描述检测靶标。
- 74%(79/107)报告包含分析灵敏度信息,83%(89/107)报告至少1项检测局限性。
- 仅34%(36/107)报告提及未检测的变异。
- 99%(106/107)包含分析性解释评论,90%(96/107)包含临床解释性评论。
- 开展实验室自建检测的参与者中,88%(88/100)纳入了关于检测开发的说明。
临床怎么用
- 分子病理报告应包含检测方法、靶标、分析灵敏度、检测局限性及未检测变异等关键要素。
- 报告应同时提供分析性和临床解释性评论,以辅助临床决策。
- 实验室自建检测需在报告中说明检测开发情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: - With enormous growth in the field of molecular pathology, the reporting of results gleaned from this testing is essential to guide patient care. OBJECTIVE: - To examine molecular reports from laboratories participating in proficiency testing for required elements to convey molecular laboratory test results to clinicians and patients. DESIGN: - Molecular laboratories participating in the College of American Pathologists (CAP) proficiency testing program for BRAF mutation analysis were solicited to submit examples of final reports from 2 separate proficiency testing reporting cycles. Reports were reviewed for the presence or absence of relevant components. RESULTS: - A total of 107 evaluable reports were received (57 demonstrating a positive result for the BRAF V600E mutation and 50 negative). Methods for BRAF testing varied, with 95% (102 of 107) of reports adequately describing their assay methods and 87% (93 of 107) of reports adequately describing the target(s) of their assays. Information on the analytic sensitivity of the assay was present in 74% (79 of 107) of reports and 83% (89 of 107) reported at least 1 assay limitation, though only 34% (36 of 107) reported on variants not detected by their assays. Analytic and clinical interpretive comments were included in 99% (106 of 107) and 90% (96 of 107) of reports, respectively. Of participants that perform a laboratory-developed test, 88% (88 of 100) included language addressing the development of the assay. CONCLUSIONS: - Laboratories participating in BRAF proficiency testing through the CAP are including most of the required reporting elements to unambiguously convey molecular results. Laboratories should continue to strive to report these results in a concise and comprehensive manner.
引用
- Treece AL, Gulley ML, Vasalos P, et al. Reporting Results of Molecular Tests: A Retrospective Examination of BRAF Mutation Reporting. Arch Pathol Lab Med. 2017. PMID: 28447902. doi:10.5858/arpa.2016-0280-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。